As of Jun 23
| +0.02 / +0.53%|
The 3 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 13.00, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a +243.92% increase from the last price of 3.78.
The current consensus among 4 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.